Abzena PLC | Income Statement

Fiscal year is April-March. All values GBP Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
3,780.00
5,667.00
9,854.00
18,654.00
21,950.00
Cost of Goods Sold (COGS) incl. D&A
2,027.00
2,532.00
5,319.00
10,547.00
12,315.00
Gross Income
1,753.00
3,135.00
4,535.00
8,107.00
9,635.00
SG&A Expense
5,932.00
8,755.00
13,263.00
18,460.00
24,761.00
EBIT
4,179.00
5,620.00
8,728.00
10,353.00
15,126.00
Unusual Expense
413.00
-
2,542.00
-
55.00
Non Operating Income/Expense
135.00
189.00
367.00
611.00
239.00
Interest Expense
-
9.00
19.00
53.00
63.00
Pretax Income
4,436.00
5,352.00
10,659.00
9,465.00
14,754.00
Income Tax
534.00
630.00
961.00
347.00
593.00
Consolidated Net Income
3,902.00
4,722.00
9,698.00
9,118.00
14,161.00
Net Income
3,902.00
4,722.00
9,698.00
9,118.00
14,161.00
Net Income After Extraordinaries
3,902.00
4,722.00
9,698.00
9,118.00
14,161.00
Net Income Available to Common
3,902.00
4,722.00
9,698.00
9,118.00
14,161.00
EPS (Basic)
0.04
0.07
0.09
0.07
0.07
Basic Shares Outstanding
97,428.90
71,615.00
109,397.00
137,177.00
209,362.00
EPS (Diluted)
0.04
0.07
0.09
0.07
0.07
Diluted Shares Outstanding
97,428.90
71,615.00
109,397.00
137,177.00
209,362.00
EBITDA
3,613.00
4,831.00
7,339.00
8,473.00
12,733.00
Non-Operating Interest Income
21.00
88.00
263.00
330.00
251.00

About Abzena

View Profile
Address
Babraham Research Campus
Cambridge Cambridgeshire CB22 3AT
United Kingdom
Employees -
Website http://abzena.com/
Updated 09/14/2018
Abzena Plc engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It operates through the following segments: Biology, Chemistry, and Biomanufacturing. Its services include: antibody discovery and candidate screening; immunology and immunogenicity assessment; antibody and protein engineering to reduce immunogenicity; and custom synthesis of cytotoxic payloads, reagents, and other small molecules.